Javier San Martin
Chief Tech/Sci/R&D Officer bij ATHIRA PHARMA, INC.
Vermogen: 6 M $ op 31-03-2024
Profiel
Op dit moment is Javier San Martin Chief Medical Officer bij Arrowhead Pharmaceuticals, Inc. Daarvoor was hij Executive Director-Bone Therapeutic Area bij Amgen, Inc., Principal bij Eli Lilly & Co., Senior VP-Global Clinical Development bij Ultragenyx Pharmaceutical, Inc. en Senior Vice President-Clinical Development bij Alder Biopharmaceuticals, Inc. Hij promoveerde aan de Universidad de Buenos Aires.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 10-01-2024 | 198 497 ( 0.16% ) | 6 M $ | 31-03-2024 |
Actieve functies van Javier San Martin
| Bedrijven | Functie | Begin |
|---|---|---|
| ATHIRA PHARMA, INC. | Chief Tech/Sci/R&D Officer | 15-04-2024 |
Eerdere bekende functies van Javier San Martin
| Bedrijven | Functie | Einde |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-02-2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01-11-2019 |
| AMGEN INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van Javier San Martin
| University of Buenos Aires School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
